Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 5/20 | 0.60 |
| ▸ | ABCC4 | O15439 | 2/20 | 0.60 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.60 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.60 |
| ▸ | TACR2 | P21452 | 2/20 | 0.60 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.60 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.60 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.60 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.60 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.60 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.60 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.60 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.60 |
| ▸ | HTR1A | P08908 | 1/20 | 0.60 |
| ▸ | DRD2 | P14416 | 1/20 | 0.60 |
| ▸ | DRD3 | P35462 | 1/20 | 0.60 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.60 |
| ▸ | HTR2B | P41595 | 1/20 | 0.60 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7292550 | 0.91 | CYP3A4 (0.60) | CYP3A4ABCC4ABCB11ABCB1TACR2 | |
| SCHEMBL13915942 | 0.88 | CYP3A4 (0.62) | CYP3A4ABCC4ABCB11ABCB1TACR2 | |
| SCHEMBL14350821 | 0.88 | CYP3A4 (0.62) | CYP3A4ABCC4ABCB11ABCB1TACR2 | |
| SCHEMBL14350789 | 0.88 | CYP3A4 (0.62) | CYP3A4ABCC4ABCB11ABCB1TACR2 | |
| SCHEMBL13908023 | 0.87 | CYP3A4 (0.61) | CYP3A4ABCC4ABCB11ABCB1TACR2 | |
| SCHEMBL5411938 | 0.87 | CYP3A4 (0.64) | CYP3A4ABCC4ABCB11ABCB1TACR2 | |
| SCHEMBL13907845 | 0.87 | CYP3A4 (0.62) | CYP3A4ABCC4ABCB11ABCB1TACR2 | |
| SCHEMBL7432585 | 0.86 | CYP3A4 (0.55) | CYP3A4ABCC4ABCB11ABCB1TACR2 | |
| SCHEMBL496314 | 0.86 | KLK5 (0.63) | CYP3A4ABCC4ABCB11ABCB1TACR2 | |
| SCHEMBL13915941 | 0.85 | CYP3A4 (0.59) | CYP3A4ABCC4ABCB11ABCB1TACR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9096576-B2 | Compounds and methods for treatment of systemic lupus erythematosus | THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH (US) | 2015-08-04 | — | — | US | disclosed |
| US-20140309255-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS | THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH (US) | 2014-10-16 | — | — | US | disclosed |
| US-8741924-B2 | Compounds and methods for treatment of systemic lupus erythematosus | THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH (US) | 2014-06-03 | — | — | US | disclosed |
| US-20130123299-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS | THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH (US) | 2013-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123299-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS | SSB, DNASE1L3, SNRPD2 | CYP3A4 4524/4885ABCC4 3590/4885ABCB11 4325/4885 |
| US-20140309255-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS | SSB, DNASE1L3, SNRPD2 | CYP3A4 4524/4885ABCC4 3590/4885ABCB11 4325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.